Free Trial

InMode Q3 2023 Earnings Report

InMode logo
$15.71 -0.59 (-3.62%)
As of 04:00 PM Eastern

InMode EPS Results

Actual EPS
$0.54
Consensus EPS
$0.53
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

InMode Revenue Results

Actual Revenue
$123.11 million
Expected Revenue
$123.00 million
Beat/Miss
Beat by +$110.00 thousand
YoY Revenue Growth
N/A

InMode Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Remove Ads

InMode Earnings Headlines

Why InMode Ltd. (NASDAQ:INMD) Could Be Worth Watching
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
INMD Crosses Below Key Moving Average Level
See More InMode Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InMode? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InMode and other key companies, straight to your email.

About InMode

InMode (NASDAQ:INMD) designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

View InMode Profile

More Earnings Resources from MarketBeat